RecruitingPhase 1Phase 2NCT05377996
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Sponsor
Day One Biopharmaceuticals, Inc.
Enrollment
360 participants
Start Date
Aug 15, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
A Study of Emi-Le in Participants with Solid Tumors
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new cancer drug called XMT-1660 — a type of antibody-drug conjugate, which is like a guided missile that targets cancer cells and delivers chemotherapy directly to them — in people with advanced or recurring solid tumors.
**You may be eligible if...**
- You have an advanced or recurrent solid tumor that has come back or progressed
- You are in good overall health (ECOG performance status 0 or 1)
- You have a tumor that can be measured or assessed by standard imaging
- You can provide a tumor tissue sample (either from a previous biopsy or a new one)
**You may NOT be eligible if...**
- You have untreated or active brain metastases that are not stable
- Your tumor tissue is not available and you cannot undergo a new biopsy
- Your overall health status is too poor to tolerate experimental treatment
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEmi-Le
Emi-Le will be administered through a vein in your arm or port catheter (intravenously)
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05377996
Related Trials
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
NCT07619534
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
NCT069257247 locations
Pulsed Electric Field Ablation for Metastatic Breast Cancer
NCT07487844
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
NCT064116781 location
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
NCT0262085211 locations